Locus coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease

Neurobiology of Stress

Volumn 2, Issue , 2015, Pages 73-84

  Ross, Jennifer A ^a   McGonigle, Paul ^a   Van Bockstaele, Elisabeth J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenergic receptors; Amyloid; Dense core vesicles; Dopamine hydroxylase; Inflammation; Stress

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; ADRENERGIC RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; NORADRENALIN;

ALZHEIMER DISEASE; ANATOMICAL VARIATION; CENTRAL NUCLEUS (AMYGDALA); ELECTRON MICROSCOPY; GABAERGIC TRANSMISSION; HUMAN; LEARNING; LOCUS CERULEUS; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; WORKING MEMORY;

EID: 84943151443     PISSN: None     EISSN: 23522895     Source Type: Journal    
DOI: 10.1016/j.ynstr.2015.09.002     Document Type: Review

References (148)

1. Abercrombie E.D., Keller R.W., Zigmond M.J. Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies. Neuroscience 1988, 27(3):897-904.
2. Aboukhatwa M., Dosanjh L., Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol. Neurodegener. 2010, 5:10. 10.1186/1750-1326-5-10.
3. Abramov E., Dolev I., Fogel H., Ciccotosto G.D., Ruff E., Slutsky I. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 2009, 12(12):1567-1576. 10.1038/nn.2433.
4. Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 1979, 135:216-223.
5. Akiyama H., Kawamata T., Yamada T., Tooyama I., Ishii T., McGeer P.L. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol. 1993, 85(6):628-634.
6. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Zschr Psychiatr. Psych. Gerichtl. Med. 1907, 64:146-148.
7. Alzheimer's Association Alzheimer's disease facts and Figures. Alzheimer's Dement. 2015, 11(3):332.
8. Aoki C., Venkatesan C., Kurose H. Noradrenergic modulation of the prefrontal cortex as revealed by electron microscopic immunocytochemistry. Adv. Pharmacol. 1998, 42:777-780.
9. Arnsten A.F., Goldman-Rakic P.S. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985, 230(4731):1273-1276.
10. Aubry J.M. CRF system and mood disorders. J. Chem. Neuroanat. 2013, 54:20-24. 10.1016/j.jchemneu.2013.09.003.
11. Bale T.L., Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 2004, 44:525-557. 10.1146/annurev.pharmtox.44.101802.121410.
12. Bangasser D.A., Curtis A., Reyes B.A., Bethea T.T., Parastatidis I., Ischiropoulos H., Valentino R.J. Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol. Psychiatry 2010, 15(9):896-904. 877. 10.1038/mp.2010.66.
13. Bangasser D.A., Zhang X., Garachh V., Hanhauser E., Valentino R.J. Sexual dimorphism in locus coeruleus dendritic morphology: a structural basis for sex differences in emotional arousal. Physiol. Behav. 2011, 103(3-4):342-351. 10.1016/j.physbeh.2011.02.037.
14. Beck C.H., Fibiger H.C. Conditioned fear-induced changes in behavior and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment. J. Neurosci. 1995, 15(1 Pt 2):709-720.
15. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 2003, 42(1):33-84.
16. Bonaz B., Tache Y. Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res. 1994, 641(1):21-28.
17. Bondareff W., Mountjoy C.Q., Roth M., Rossor M.N., Iversen L.L., Reynolds G.P., Hauser D.L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1987, 1(4):256-262.
18. Braak H., Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. Acta Neuropathol. 2011, 121(5):589-595. 10.1007/s00401-011-0825-z.
19. Britton K.T., Segal D.S., Kuczenski R., Hauger R. Dissociation between in vivo hippocampal norepinephrine response and behavioral/neuroendocrine responses to noise stress in rats. Brain Res. 1992, 574(1-2):125-130.
20. Brody D.L., Magnoni S., Schwetye K.E., Spinner M.L., Esparza T.J., Stocchetti N., Holtzman D.M. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008, 321(5893):1221-1224. 10.1126/science.1161591.
21. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25(34):7709-7717. 10.1523/JNEUROSCI.2177-05.2005.
22. Campbell S.N., Zhang C., Roe A.D., Lee N., Lao K.U., Monte L., Rissman R.A. Impact of CRFR1 Ablation on amyloid-beta production and accumulation in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2015, 45(4):1175-1184. 10.3233/JAD-142844.
23. Campbell S.N., Zhang C., Monte L., Roe A.D., Rice K.C., Tache Y., Rissman R.A. Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. J. Alzheimers Dis. 2015, 43(3):967-976. 10.3233/JAD-141281.
24. Campeau S., Watson S.J. Neuroendocrine and behavioral responses and brain pattern of c-fos induction associated with audiogenic stress. J. Neuroendocrinol. 1997, 9(8):577-588.
25. Carter M.E., Brill J., Bonnavion P., Huguenard J.R., Huerta R., de Lecea L. Mechanism for Hypocretin-mediated sleep-to-wake transitions. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(39):E2635-E2644. 10.1073/pnas.1202526109.
26. Catania C., Sotiropoulos I., Silva R., Onofri C., Breen K.C., Sousa N., Almeida O.F. The amyloidogenic potential and behavioral correlates of stress. Mol. Psychiatry 2009, 14(1):95-105. 10.1038/sj.mp.4002101.
27. Chabrier M.A., Cheng D., Castello N.A., Green K.N., LaFerla F.M. Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. Neurobiol. Dis. 2014, 64:107-117. 10.1016/j.nbd.2014.01.007.
28. Chan R.K., Sawchenko P.E. Hemodynamic regulation of tyrosine hydroxylase messenger RNA in medullary catecholamine neurons: a c-fos-guided hybridization histochemical study. Neuroscience 1995, 66(2):377-390.
29. Chang M.S., Sved A.F., Zigmond M.J., Austin M.C. Increased transcription of the tyrosine hydroxylase gene in individual locus coeruleus neurons following footshock stress. Neuroscience 2000, 101(1):131-139.
30. Chen Y., Andres A.L., Frotscher M., Baram T.Z. Tuning synaptic transmission in the hippocampus by stress: the CRH system. Front. Cell Neurosci. 2012, 6:13. 10.3389/fncel.2012.00013.
31. Chen Y., Peng Y., Che P., Gannon M., Liu Y., Li L., Wang Q. alpha(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(48):17296-17301. 10.1073/pnas.1409513111.
32. Cheng X., Wu J., Geng M., Xiong J. Role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease. Neurobiol. Aging 2014, 35(6):1217-1232. 10.1016/j.neurobiolaging.2013.11.021.
33. Cho H., Seo S.W., Jeon S., Kang S.J., Kim G.H., Noh Y., Na D.L. Acceleration of cortical thinning in women with Alzheimer's disease. Alzheimer's Dement. J. Alzheimer's Assoc. 2013, 9(4):P747-P748. 10.1016/j.jalz.2013.05.1510.
34. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Holtzman D.M. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 2003, 23(26):8844-8853.
35. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48(6):913-922. 10.1016/j.neuron.2005.10.028.
36. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008, 58(1):42-51. 10.1016/j.neuron.2008.02.003.
37. Csernansky J.G., Dong H., Fagan A.M., Wang L., Xiong C., Holtzman D.M., Morris J.C. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry 2006, 163(12):2164-2169. 10.1176/appi.ajp.163.12.2164.
38. Curtis A.L., Bethea T., Valentino R.J. Sexually dimorphic responses of the brain norepinephrine system to stress and corticotropin-releasing factor. Neuropsychopharmacology 2006, 31(3):544-554. 10.1038/sj.npp.1300875.
39. Dickstein D.L., Brautigam H., Stockton S.D., Schmeidler J., Hof P.R. Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct. Funct. 2010, 214(2-3):161-179. 10.1007/s00429-010-0245-1.
40. Dong H., Goico B., Martin M., Csernansky C.A., Bertchume A., Csernansky J.G. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 2004, 127(3):601-609. 10.1016/j.neuroscience.2004.05.040.
41. Dong H., Yuede C.M., Yoo H.S., Martin M.V., Deal C., Mace A.G., Csernansky J.G. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience 2008, 155(1):154-163. 10.1016/j.neuroscience.2008.05.017.
42. Dong H., Murphy K.M., Meng L., Montalvo-Ortiz J., Zeng Z., Kolber B.J., Csernansky J.G. Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2012, 28(3):579-592. 10.3233/JAD-2011-111328.
43. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Solanezumab Study G. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370(4):311-321. 10.1056/NEJMoa1312889.
44. Drake C., Richardson G., Roehrs T., Scofield H., Roth T. Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep 2004, 27(2):285-291.
45. Duygu, T., Insel, P.S., Weiner, M.S., ApoE-ε4 Genotype by Gender Interactions in Regional Amyloid Accumulation in Alzheimer's Disease Continuum [Press Briefing part 4 of 6]. Retrieved from . https://www.alz.org/aaic/videos/video-tuesday2015.asp.
46. Elgh E., Lindqvist Astot A., Fagerlund M., Eriksson S., Olsson T., Nasman B. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol. Psychiatry 2006, 59(2):155-161. 10.1016/j.biopsych.2005.06.017.
47. Fadda P., Fratta W. Stress-induced sleep deprivation modifies corticotropin releasing factor (CRF) levels and CRF binding in rat brain and pituitary. Pharmacol. Res. 1997, 35(5):443-446. 10.1006/phrs.1997.0155.
48. Feinstein D.L., Heneka M.T., Gavrilyuk V., Dello Russo C., Weinberg G., Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 2002, 41(5):357-365.
49. Fillenz M., Lowry J.P. Studies of the source of glucose in the extracellular compartment of the rat brain. Dev. Neurosci. 1998, 20(4-5):365-368.
50. Finkel S.I. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J. Clin. Psychiatry 2001, 21(62 Suppl. l):3-6.
51. Frohman E.M., Vayuvegula B., Gupta S., van den Noort S. Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(4):1292-1296.
52. Fronczek R., van Geest S., Frolich M., Overeem S., Roelandse F.W., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 2012, 33(8):1642-1650. 10.1016/j.neurobiolaging.2011.03.014.
53. Goldstein J.M., Jerram M., Abbs B., Whitfield-Gabrieli S., Makris N. Sex differences in stress response circuitry activation dependent on female hormonal cycle. J. Neurosci. 2010, 30(2):431-438. 10.1523/JNEUROSCI.3021-09.2010.
54. Green K.N., Billings L.M., Roozendaal B., McGaugh J.L., LaFerla F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2006, 26(35):9047-9056. 10.1523/JNEUROSCI.2797-06.2006.
55. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 1995, 54(2):276-281.
56. Groemer T.W., Thiel C.S., Holt M., Riedel D., Hua Y., Huve J., Klingauf J. Amyloid precursor protein is trafficked and secreted via synaptic vesicles. PLoS One 2011, 6(4):e18754. 10.1371/journal.pone.0018754.
57. Haass C., Kaether C., Thinakaran G., Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012, 2(5):a006270. 10.1101/cshperspect.a006270.
58. Hajos M., Hoffmann W.E., Robinson D.D., Yu J.H., Hajos-Korcsok E. Norepinephrine but not serotonin reuptake inhibitors enhance theta and gamma activity of the septo-hippocampal system. Neuropsychopharmacology 2003, 28(5):857-864. 10.1038/sj.npp.1300116.
59. Hebda-Bauer E.K., Simmons T.A., Sugg A., Ural E., Stewart J.A., Beals J.L., Akil H. 3xTg-AD mice exhibit an activated central stress axis during early-stage pathology. J. Alzheimers Dis. 2013, 33(2):407-422. 10.3233/JAD-2012-121438.
60. Heneka M.T. Inflammation in Alzheimer's disease. Clin. Neurosci. Res. 2006, 6(5):247-260. 10.1016/j.cnr.2006.09.005.
61. Heneka M.T., Feinstein D.L. Expression and function of inducible nitric oxide synthase in neurons. J. Neuroimmunol. 2001, 114(1-2):8-18.
62. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Feinstein D.L. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 2002, 22(7):2434-2442. 20026222.
63. Hinojosa A.E., Caso J.R., Garcia-Bueno B., Leza J.C., Madrigal J.L. Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediators. J. Neuroinflammation 2013, 10(1):81. 10.1186/1742-2094-10-81.
64. Hong L., Huang H.C., Jiang Z.F. Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer's disease. Neurol. Res. 2014, 36(3):276-282. 10.1179/1743132813Y.0000000288.
65. Horvath T.L., Peyron C., Diano S., Ivanov A., Aston-Jones G., Kilduff T.S., van Den Pol A.N. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol. 1999, 415(2):145-159.
66. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., Gonzalez M.I. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004, 1017(1-2):130-136. 10.1016/j.brainres.2004.05.029.
67. Iversen L.L., Rossor M.N., Reynolds G.P., Hills R., Roth M., Mountjoy C.Q., Bloom F.E. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci. Lett. 1983, 39(1):95-100.
68. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9(1):119-128. 10.1016/S1474-4422(09)70299-6.
69. Jensen O., Kaiser J., Lachaux J.P. Human gamma-frequency oscillations associated with attention and memory. Trends Neurosci. 2007, 30(7):317-324. 10.1016/j.tins.2007.05.001.
70. Jeong Y.H., Park C.H., Yoo J., Shin K.Y., Ahn S.M., Kim H.S., Suh Y.H. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 2006, 20(6):729-731. 10.1096/fj.05-4265fje.
71. Ju Y.E., Lucey B.P., Holtzman D.M. Sleep and Alzheimer disease pathology-a bidirectional relationship. Nat. Rev. Neurol. 2014, 10(2):115-119. 10.1038/nrneurol.2013.269.
72. Kalaria R.N., Stockmeier C.A., Harik S.I. Brain microvessels are innervated by locus ceruleus noradrenergic neurons. Neurosci. Lett. 1989, 97(1-2):203-208.
73. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Malinow R. APP processing and synaptic function. Neuron 2003, 37(6):925-937.
74. Kang J.E., Cirrito J.R., Dong H., Csernansky J.G., Holtzman D.M. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(25):10673-10678. 10.1073/pnas.0700148104.
75. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326(5955):1005-1007. 10.1126/science.1180962.
76. Koenig T., Prichep L., Dierks T., Hubl D., Wahlund L.O., John E.R., Jelic V. Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2005, 26(2):165-171. 10.1016/j.neurobiolaging.2004.03.008.
77. Lante F., Chafai M., Raymond E.F., Pereira A.R., Mouska X., Kootar S., Marie H. Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2015, 40(7):1772-1781. 10.1038/npp.2015.25.
78. Lassmann H., Weiler R., Fischer P., Bancher C., Jellinger K., Floor E., Winkler H. Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience 1992, 46(1):1-8.
79. Lechner T., Adlassnig C., Humpel C., Kaufmann W.A., Maier H., Reinstadler-Kramer K., Marksteiner J. Chromogranin peptides in Alzheimer's disease. Exp. Gerontol. 2004, 39(1):101-113.
80. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62(6):788-801. 10.1016/j.neuron.2009.05.012.
81. Lin K.A., Doraiswamy P.M. When Mars versus Venus is not a Cliche: gender differences in the neurobiology of Alzheimer's disease. Front. Neurol. 2014, 5:288. 10.3389/fneur.2014.00288.
82. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2005, 2(2):155-165.
83. Liu Q.S., Xu Q., Kang J., Nedergaard M. Astrocyte activation of presynaptic metabotropic glutamate receptors modulates hippocampal inhibitory synaptic transmission. Neuron Glia Biol. 2004, 1(4):307-316. 10.1017/S1740925X05000190.
84. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., Breitner J.C. Mental and behavioral disturbances in dementia: findings from the Cache county study on memory in aging. Am. J. Psychiatry 2000, 157(5):708-714.
85. Lyketsos C.G., Lopez O., Jones B., Fitzpatrick A.L., Breitner J., DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002, 288(12):1475-1483.
86. Mackenzie I.R., Miller L.A. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994, 87(5):504-510.
87. Madrigal J.L., Leza J.C., Polak P., Kalinin S., Feinstein D.L. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci. 2009, 29(1):263-267. 10.1523/JNEUROSCI.4926-08.2009.
88. Makino S., Smith M.A., Gold P.W. Regulatory role of glucocorticoids and glucocorticoid receptor mRNA levels on tyrosine hydroxylase gene expression in the locus coeruleus during repeated immobilization stress. Brain Res. 2002, 943(2):216-223.
89. Markesbery W.R. The role of oxidative stress in Alzheimer disease. Arch. Neurol. 1999, 56(12):1449-1452.
90. Matthews K.L., Chen C.P., Esiri M.M., Keene J., Minger S.L., Francis P.T. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 2002, 51(5):407-416.
91. McKeith I., Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005, 4(11):735-742. 10.1016/S1474-4422(05)70219-2.
92. Mega M.S., Cummings J.L., Fiorello T., Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996, 46(1):130-135.
93. Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology 2001, 25(5 Suppl. l):S5-S13. 10.1016/S0893-133X(01)00316-5.
94. Mirmiran M., Swaab D.F., Kok J.H., Hofman M.A., Witting W., Van Gool W.A. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog. Brain Res. 1992, 93:151-162. discussion 162-153.
95. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011, 21(1):103-115. 10.1038/cr.2010.178.
96. Mravec B., Lejavova K., Cubinkova V. Locus (coeruleus) minoris resistentiae in pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2014, 11(10):992-1001.
97. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., Thal L.J. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's disease cooperative study. JAMA 2000, 283(8):1007-1015.
98. Murchison C.F., Zhang X.Y., Zhang W.P., Ouyang M., Lee A., Thomas S.A. A distinct role for norepinephrine in memory retrieval. Cell 2004, 117(1):131-143.
99. Nagaratnam N., Lewis-Jones M., Scott D., Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Dis. Assoc. Disord. 1998, 12(4):330-334.
100. Ni Y., Zhao X., Bao G., Zou L., Teng L., Wang Z., Pei G. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat. Med. 2006, 12(12):1390-1396. 10.1038/nm1485.
101. O'Donnell J., Zeppenfeld D., McConnell E., Pena S., Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res. 2012, 37(11):2496-2512. 10.1007/s11064-012-0818-x.
102. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009, 66(4):435-440. 10.1001/archneurol.2009.15.
103. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13(7):812-818. 10.1038/nn.2583.
104. Palop J.J., Chin J., Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006, 443(7113):768-773. 10.1038/nature05289.
105. Perez-Cruz C., Nolte M.W., van Gaalen M.M., Rustay N.R., Termont A., Tanghe A., Ebert U. Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J. Neurosci. 2011, 31(10):3926-3934. 10.1523/JNEUROSCI.6142-10.2011.
106. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18(23):9996-10015.
107. Pollak C.P., Perlick D. Sleep problems and institutionalization of the elderly. J. Geriatr. Psychiatry Neurol. 1991, 4(4):204-210.
108. Ramos B.P., Arnsten A.F. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol. Ther. 2007, 113(3):523-536. 10.1016/j.pharmthera.2006.11.006.
109. Rasmuson S., Andrew R., Nasman B., Seckl J.R., Walker B.R., Olsson T. Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease. Biol. Psychiatry 2001, 49(6):547-552.
110. Reyes B.A., Valentino R.J., Xu G., Van Bockstaele E.J. Hypothalamic projections to locus coeruleus neurons in rat brain. Eur. J. Neurosci. 2005, 22(1):93-106. 10.1111/j.1460-9568.2005.04197.x.
111. Rissman R.A., Lee K.F., Vale W., Sawchenko P.E. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J. Neurosci. 2007, 27(24):6552-6562. 10.1523/JNEUROSCI.5173-06.2007.
112. Rissman R.A., Staup M.A., Lee A.R., Justice N.J., Rice K.C., Vale W., Sawchenko P.E. Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(16):6277-6282. 10.1073/pnas.1203140109.
113. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31(2):700-711. 10.1523/JNEUROSCI.4152-10.2011.
114. Roh J.H., Jiang H., Finn M.B., Stewart F.R., Mahan T.E., Cirrito J.R., Holtzman D.M. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. J. Exp. Med. 2014, 211(13):2487-2496. 10.1084/jem.20141788.
115. Roozendaal B., Nguyen B.T., Power A.E., McGaugh J.L. Basolateral amygdala noradrenergic influence enables enhancement of memory consolidation induced by hippocampal glucocorticoid receptor activation. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(20):11642-11647.
116. Roozendaal B., McReynolds J.R., McGaugh J.L. The basolateral amygdala interacts with the medial prefrontal cortex in regulating glucocorticoid effects on working memory impairment. J. Neurosci. 2004, 24(6):1385-1392. 10.1523/JNEUROSCI.4664-03.2004.
117. Seshadri S., Wolf P.A., Beiser A., Au R., McNulty K., White R., D'Agostino R.B. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 1997, 49(6):1498-1504.
118. Sink K.M., Covinsky K.E., Newcomer R., Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J. Am. Geriatr. Soc. 2004, 52(8):1277-1283. 10.1111/j.1532-5415.2004.52356.x.
119. Sisodia S.S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(13):6075-6079.
120. Sisodia S.S. Secretion of the beta-amyloid precursor protein. Ann. N. Y. Acad. Sci. 1992, 674:53-57.
121. Smith D.L., Pozueta J., Gong B., Arancio O., Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(39):16877-16882. 10.1073/pnas.0908706106.
122. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8(8):1051-1058. 10.1038/nn1503.
123. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7(3):280-292. 10.1016/j.jalz.2011.03.003.
124. Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M.W., Okamoto S., Lipton S.A. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(27):E2518-E2527. 10.1073/pnas.1306832110.
125. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348(9025):429-432. 10.1016/S0140-6736(96)03356-9.
126. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58(12):1791-1800.
127. Thathiah A., Horre K., Snellinx A., Vandewyer E., Huang Y., Ciesielska M., De Strooper B. beta-arrestin 2 regulates Abeta generation and gamma-secretase activity in Alzheimer's disease. Nat. Med. 2013, 19(1):43-49. 10.1038/nm.3023.
128. Toneff T., Funkelstein L., Mosier C., Abagyan A., Ziegler M., Hook V. Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters. Peptides 2013, 46:126-135. 10.1016/j.peptides.2013.04.020.
129. Tractenberg R.E., Singer C.M., Cummings J.L., Thal L.J. The sleep disorders inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J. Sleep. Res. 2003, 12(4):331-337.
130. Traub R.D., Cunningham M.O., Gloveli T., LeBeau F.E., Bibbig A., Buhl E.H., Whittington M.A. GABA-enhanced collective behavior in neuronal axons underlies persistent gamma-frequency oscillations. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(19):11047-11052. 10.1073/pnas.1934854100.
131. Tully K., Bolshakov V.Y. Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. Mol. Brain 2010, 3:15. 10.1186/1756-6606-3-15.
132. Valentino R.J., Foote S.L., Aston-Jones G. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 1983, 270(2):363-367.
133. Valentino R.J., Page M., Van Bockstaele E., Aston-Jones G. Corticotropin-releasing factor innervation of the locus coeruleus region: distribution of fibers and sources of input. Neuroscience 1992, 48(3):689-705.
134. Valentino R.J., Bangasser D., Van Bockstaele E.J. Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model. Mol. Pharmacol. 2013, 83(4):737-745. 10.1124/mol.112.083550.
135. Van Bockstaele E.J., Valentino R.J. Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur. J. Neurosci. 2008, 583(2-3):194-203.
136. Van Bockstaele E.J., Colago E.E., Valentino R.J. Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites: substrate for the co-ordination of emotional and cognitive limbs of the stress response. J. Neuroendocrinol. 1998, 10(10):743-757.
137. Verret L., Mann E.O., Hang G.B., Barth A.M., Cobos I., Ho K., Palop J.J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149(3):708-721. 10.1016/j.cell.2012.02.046.
138. Vitiello M.V., Borson S. Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment. CNS Drugs 2001, 15(10):777-796.
139. Vitiello M.V., Prinz P.N., Williams D.E., Frommlet M.S., Ries R.K. Sleep disturbances in patients with mild-stage Alzheimer's disease. J. Gerontol. 1990, 45(4):M131-M138.
140. Wang Z.-W., ebrary Inc Molecular Mechanisms of Neurotransmitter Release Contemporary Neuroscience 2008, (pp. xiii, 347 pages).
141. Wang D., Yuen E.Y., Zhou Y., Yan Z., Xiang Y.K. Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J. Biol. Chem. 2011, 286(36):31852-31863. 10.1074/jbc.M111.244335.
142. Waterhouse B.D., Moises H.C., Woodward D.J. Noradrenergic modulation of somatosensory cortical neuronal responses to iontophoretically applied putative neurotransmitters. Exp. Neurol. 1980, 69(1):30-49.
143. Weiner M.F., Vobach S., Olsson K., Svetlik D., Risser R.C. Cortisol secretion and Alzheimer's disease progression. Biol. Psychiatry 1997, 42(11):1030-1038.
144. Wilson R.S., Evans D.A., Bienias J.L., Mendes de Leon C.F., Schneider J.A., Bennett D.A. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 2003, 61(11):1479-1485.
145. Wilson R.S., Barnes L.L., Bennett D.A., Li Y., Bienias J.L., Mendes de Leon C.F., Evans D.A. Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology 2005, 64(2):380-382. 10.1212/01.WNL.0000149525.53525.E7.
146. Xu H., Gouras G.K., Greenfield J.P., Vincent B., Naslund J., Mazzarelli L., Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 1998, 4(4):447-451.
147. Yu J.T., Tan L., Ou J.R., Zhu J.X., Liu K., Song J.H., Sun Y.P. Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. Brain Res. 2008, 1210:216-222. 10.1016/j.brainres.2008.03.019.
148. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 2003, 60(3):337-341.